Secukinumab is effective in reducing dactylitis and enthesitis using multiple measures in patients with psoriatic arthritis: Results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study (FUTURE 2)

被引：0
|
作者：
Mease, P. [1 ,2 ]
Kirkham, B. [3 ]
McInnes, I. B. [4 ]
Kremer, J. [5 ,6 ]
Kandala, S. [7 ]
Pricop, L. [8 ]
Mpofu, S. [9 ]
机构：
[1] Swedish Med Ctr, Seattle, WA USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Guys & St Thomas NHS Fdn Trust, London, England
[4] Univ Glasgow, Glasgow, Lanark, Scotland
[5] Albany Med Coll, Albany, NY 12208 USA
[6] Ctr Rheumatol, New York, NY USA
[7] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
[8] Novartis Pharmaceut, Orange, NJ USA
[9] Novartis Pharma AG, Basel, Switzerland
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2015年 / 135卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P115
引用
收藏
页码：S30 / S30
页数：1
相关论文
共 50 条
  • [1] SECUKINUMAB IS EFFECTIVE IN REDUCING DACTYLITIS AND ENTHESITIS USING MULTIPLE MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS: DATA FROM A PHASE 3 RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (FUTURE 2)
    Kirkham, B.
    McInnes, I. B.
    Mease, P.
    Kremer, J.
    Kandala, S.
    Pricop, L.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 351 - 351
  • [2] Secukinumab is effective in reducing dactylitis and enthesitis using multiple measures in patients with psoriatic arthritis: Results from two phase 3 randomized, multicenter, double-blind, placebo-controlled studies (FUTURE 1 and 2)
    Gottlieb, Alice
    McInnes, Iain
    Mease, Philip
    Mpofu, Shephard
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB271 - AB271
  • [3] SECUKINUMAB PROVIDES RAPID AND SUSTAINED REDUCTIONS IN DACTYLITIS AND ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF DATA FROM THE PHASE 3 RANDOMIZED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED FUTURE 2 STUDY
    Kirkham, Bruce
    Mease, Philip J.
    McInnes, Iain B.
    RHEUMATOLOGY, 2017, 56 : 77 - 77
  • [4] SECUKINUMAB PROVIDES RAPID AND SUSTAINED REDUCTIONS IN DACTYLITIS AND ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF DATA FROM THE PHASE 3 RANDOMISED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED FUTURE 2 STUDY
    Kirkham, B.
    Mease, P.
    McInnes, I.
    Bhosekar, V.
    Mpofu, S.
    Gandhi, K.
    Gaillez, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 599 - 600
  • [5] Secukinumab improves active psoriatic arthritis and inhibits radiographic progression: Results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study
    Mease, P.
    McInnes, I. B.
    Kirkham, B.
    Kavanaugh, A.
    Rahman, P.
    Van Der Heijde, D.
    Landewe, R.
    Nash, P.
    Pricop, L.
    Yuan, J.
    Richards, H.
    Mpofu, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S29 - S29
  • [6] SECUKINUMAB INHIBITS RADIOGRAPHIC PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS: DATA FROM A PHASE 3 RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (FUTURE 1)
    Van der Heijde, D.
    Landewe, R.
    Mease, P.
    McInnes, I. B.
    Conaghan, P. G.
    Pricop, L.
    Ligozio, G.
    Richards, H.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 347 - 348
  • [7] Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study
    Zou, Hejian
    Wan, Weiguo
    Xue, Yu
    Sun, Lingyun
    Zhang, Ning
    Chen, Haiying
    Shi, Xiaofei
    Liu, Shengyun
    Chen, Lin
    Ma, Xinmei
    Wei, Hua
    Jiang, Zhenyu
    Li, Xiaomei
    Fan, Hongtao
    Li, Hongbin
    Li, Jingyang
    Wu, Rui
    Shi, Guixiu
    Zhu, Jing
    Kong, Xiaodan
    Lu, Yuewu
    Cui, Xiaojing
    Zheng, Qianning
    Bai, Xiaoyan
    Dong, Guangchao
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 5240 - 5242
  • [8] Secukinumab improves signs and symptoms of active psoriatic arthritis: Results from a phase 3 randomized, multicenter, double-blind, placebo-controlled study using a subcutaneous dosing regimen (FUTURE 2)
    Gottlieb, A. B.
    McInnes, I. B.
    Mease, P.
    Kirkham, B.
    Kavanaugh, A.
    Ligozio, G.
    Pricop, L.
    Mpofu, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S29 - S29
  • [9] SECUKINUMAB IMPROVES SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS IN A PHASE 3 RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY USING A SUBCUTANEOUS DOSING REGIMEN (FUTURE 2)
    McInnes, I. B.
    Mease, P.
    Kirkham, B.
    Kavanaugh, A.
    Ritchlin, C.
    Rahman, P.
    Van der Heijde, D.
    Landewe, R.
    Conaghan, P. G.
    Gottlieb, A. B.
    Richards, H.
    Ligozio, G.
    Pricop, L.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 352 - 353
  • [10] Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial
    Brunner, Hermine, I
    Foeldvari, Ivan
    Alexeeva, Ekaterina
    Ayaz, Nuray Aktay
    Calvo Penades, Inmaculada
    Kasapcopur, Ozgur
    Chasnyk, Vyacheslav G.
    Hufnagel, Markus
    Zuber, Zbigniew
    Schulert, Grant
    Ozen, Seza
    Rakhimyanova, Adelina
    Ramanan, Athimalaipet
    Scott, Christiaan
    Sozeri, Betul
    Zholobova, Elena
    Martin, Ruvie
    Zhu, Xuan
    Whelan, Sarah
    Pricop, Luminita
    Martini, Alberto
    Lovell, Daniel
    Ruperto, Nicolino
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (01) : 154 - 160
12345